Adaptive Biotechnologies Corporation reports results for the quarter ended September 30 - Earnings Summary

Adaptive Biotechnologies

04/11/2026 22:45

Adaptive Biotechnologies Corporation ADPT.OQ reported quarterly adjusted earnings of 2 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 6 cents.  The mean expectation of nine analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -11 cents to -6 cents per share.
Revenue fell 10.7% to $83.90 million from a year ago; analysts expected $71.60 million. 
Adaptive Biotechnologies Corporation's reported EPS for the quarter was 2 cents​.
The company reported quarterly net income of $2.88 million.
Adaptive Biotechnologies Corporation shares had fallen by 10.7% this quarter and gained 58.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 4.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Adaptive Biotechnologies Corporation is $31.00, about 16.8% above its last closing price of $25.80
This summary was machine generated from LSEG data November 4 at 10:45 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.10
0.02
Beat
Jun. 30 2026 
-0.13
-0.10
Beat
Mar. 31 2026 
-0.16
-0.12
Beat
Dec. 31 2025 
-0.18
-0.09
Beat